IMPACT Therapeutics
PublicIMPACT Therapeutics is now publicly traded
The data on this page reflects IMPACT Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Mar 27, 2026
Last Round
Series D
Extension
Nov 15, 2024
Total Funding Raised
$169.7M
Company Overview
IMPACT Therapeutics has raised $169.7M. It was founded in 2009.
IMPACT Therapeutics is a biotechnology company that develops synthetic lethality-based precision anti-cancer therapies.
AI Layer
Non-AI
IMPACT Therapeutics Comparables
Compare IMPACT Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| HaiHe Biopharma | 79% | |
| SynRx Therapeutics | 76% | |
| SciBrunch Therapeutics | 74% |
For institutional investors. Book with your work email.
IMPACT Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Mar 27, 2026 | ||||
| Series D Extension | Nov 15, 2024 | ||||
| Series D Extension | Apr 22, 2024 | ||||
| Series D | Mar 14, 2022 | ||||
| Series C Extension | Nov 30, 2020 | ||||
Series C | Aug 3, 2018 |
For institutional investors. Book with your work email.
IMPACT Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Dingxin Capital | Series D |
| Xiamen C&D Emerging Industry Equity Investment | Series D Extension |
| Exome Asset Management | Series D |
| Lilly Asia Ventures | Series D, Series D Extension, Series C Extension, Series C |
| Decheng Capital | Series C |
IMPACT Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.